{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:19:40Z","timestamp":1795094380790,"version":"4.10.2"},"reference-count":35,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in treating relapsed and refractory (R\/R) B-cell neoplasms, such as diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Despite its success, the long-term effects and sequelae of CAR T cells on the immune system remain underexplored. This study presents a 1-year follow-up analysis of 52 patients (42 with R\/R DLBCL and 10 with R\/R MM) treated with anti-CD19\u2013 and B-cell maturation antigen-targeted CAR T cells, focusing on immune reconstitution and infectious complications. Our findings reveal that CAR T-cell therapy leads to profound depletion of B and T cells. CD4+ T cells and CD19+ B cells exhibited impaired regeneration after treatment. Infections were more frequent during the first 30 days. In the short-term follow-up, density of infections within 100 days at risk was 1.8 in patients with DLBCL and 4.6 in patients with MM, with bacterial infections predominating in this early period after CAR T-cell infusion. In addition, we observed a shift to viral infections in the long-term follow-up, alongside with a decline in infection density to 0.1 in patients with DLBCL and 0.4 infections per 100 days at risk in patients with MM, respectively. Severe cytokine release syndrome was associated with a higher risk of late-onset infections. These findings highlight the importance of close monitoring and prophylactic measures in patients undergoing CAR T-cell therapy to reduce infection risks and enhance immune recovery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015346","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:18:01Z","timestamp":1743959881000},"page":"3149-3158","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-7373","authenticated-orcid":false,"given":"Andreas","family":"Riedel","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Phely","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hug","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0025-0057","authenticated-orcid":false,"given":"Philipp","family":"Faustmann","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-4427","authenticated-orcid":false,"given":"Jan Christian","family":"Schroeder","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Besemer","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3794-5003","authenticated-orcid":false,"given":"Anna M.","family":"Paczulla Stanger","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Frederic","family":"Weller","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"2Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"1","key":"2025070811265890300_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2025070811265890300_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10297","key":"2025070811265890300_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025070811265890300_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"2025070811265890300_bib5","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"2025070811265890300_bib6","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025070811265890300_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"issue":"10","key":"2025070811265890300_bib8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"10","key":"2025070811265890300_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2025070811265890300_bib10","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025070811265890300_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"35","key":"2025070811265890300_bib12","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025070811265890300_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2025070811265890300_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025070811265890300_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025070811265890300_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2025070811265890300_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025070811265890300_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-94353-0_29","volume-title":"The EBMT\/EHA CAR-T Cell Handbook","author":"Subklewe","year":"2022"},{"issue":"8","key":"2025070811265890300_bib19","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","article-title":"Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"21","key":"2025070811265890300_bib20","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"2025070811265890300_bib21","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2025070811265890300_bib22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2025070811265890300_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2025070811265890300_bib24","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2025070811265890300_bib25","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2025070811265890300_bib26","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2025070811265890300_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.humimm.2018.10.015","article-title":"Primary B-cell immunodeficiencies","volume":"80","author":"Smith","year":"2019","journal-title":"Hum Immunol"},{"issue":"1","key":"2025070811265890300_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hoc.2010.11.008","article-title":"Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology","volume":"25","author":"Wingard","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"16","key":"2025070811265890300_bib29","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2025070811265890300_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"6","key":"2025070811265890300_bib31","doi-asserted-by":"crossref","first-page":"ofae133","DOI":"10.1093\/ofid\/ofae133","article-title":"The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 1","key":"2025070811265890300_bib32","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"2025070811265890300_bib33","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2025070811265890300_bib34","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2025070811265890300_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3149\/2381624\/blooda_adv-2024-015346-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3149\/2381624\/blooda_adv-2024-015346-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:27:05Z","timestamp":1751988425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3149\/536582\/Immunological-consequences-of-CAR-T-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015346","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,6,25]]}}}